# Insulin Glargine

Canonical source: https://retacompare.com/encyclopedia/insulin-glargine

Long-acting basal insulin analog. pH-dependent solubility creates a depot in subcutaneous tissue.

Reference facts

Also known asLantus, Toujeo, BasaglarCategoryHormonal & PituitaryMechanism of actionLong-acting basal insulin analog. pH-dependent solubility creates a depot in subcutaneous tissue.TargetsInsulin receptorIndications under research or approvedDiabetes type 1 and 2 — basal insulin replacementRegulatory status (reference entry)FDA-approved (2000)Half-life~12 hours (effective duration ~24 hours)SequenceGIVEQCCTSICSLYQLENYCGSequence notesModified insulin: A-chain Asn21 → Gly; B-chain extended with Arg-Arg at C-terminus, forming microprecipitates at neutral subcutaneous pH for prolonged release.Molecular weight (Da)6063Originator / sponsorSanofi (Lantus); Eli Lilly (Basaglar biosimilar)First reported1996
    Primary References

Lantus FDA label


    Explore research articles about Insulin Glargine


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- Lantus FDA label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021081s063lbl.pdf